Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Apter

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|December 14, 2002
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trialHelena von Hertzen, Gilda Piaggio, Juhong Ding, et al.
International Journal of Cancer|November 22, 2019
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated womenKarolina Louvanto, Tiina Eriksson, Penelope Gray, et al.
BMJ Open|February 12, 2022
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trialMatti Lehtinen, Camilla Lagheden, Tapio Luostarinen, et al.
International Journal of STD & AIDS|August 24, 2006
Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessingMatti Lehtinen, Dan Apter, Gary Dubin, et al.
The Lancet. Global Health|June 25, 2019
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trialsDavid F Archer, Ruth B Merkatz, Luis Bahamondes, et al.
International Journal of Cancer|October 22, 2017
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I)Matti Lehtinen, Anna Söderlund-Strand, Simopekka Vänskä, et al.
International Journal of Cancer|May 31, 2018
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)Matti Lehtinen, Tapio Luostarinen, Simopekka Vänskä, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2008
Male hormonal contraception: a double-blind, placebo-controlled studyEllen Mommers, Wendy M Kersemaekers, Jörg Elliesen, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|December 14, 2002
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trialHelena von Hertzen, Gilda Piaggio, Juhong Ding, et al.
International Journal of Cancer|November 22, 2019
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated womenKarolina Louvanto, Tiina Eriksson, Penelope Gray, et al.
BMJ Open|February 12, 2022
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trialMatti Lehtinen, Camilla Lagheden, Tapio Luostarinen, et al.
International Journal of STD & AIDS|August 24, 2006
Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessingMatti Lehtinen, Dan Apter, Gary Dubin, et al.
The Lancet. Global Health|June 25, 2019
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trialsDavid F Archer, Ruth B Merkatz, Luis Bahamondes, et al.
International Journal of Cancer|October 22, 2017
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I)Matti Lehtinen, Anna Söderlund-Strand, Simopekka Vänskä, et al.
International Journal of Cancer|May 31, 2018
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)Matti Lehtinen, Tapio Luostarinen, Simopekka Vänskä, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2008
Male hormonal contraception: a double-blind, placebo-controlled studyEllen Mommers, Wendy M Kersemaekers, Jörg Elliesen, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Pageof 9